Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy dataCharles E. Geyer, David Cameron, Anne Marie Martin et al.|Journal of Clinical Oncology|2007Cited by 32
Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous MelanomaCaroline Robert, Dirk Schadendorf, Andrzej Maćkiewicz et al.|Annals of Oncology|2014Cited by 7